Invitrocue

Invitrocue is a life sciences company headquartered in Singapore. The company employs 36 people and generates $0.578 million in annual revenue. Invitrocue specializes in developing innovative 3D cell-based models, particularly Patient-Derived Organoids from solid cancers. Their Onco-PDO test utilizes these models to perform in vitro drug screenings, providing oncologists with crucial information to personalize patient therapy. Invitrocue's technology enables the culture of patient-derived cancer cells in laboratories, allowing for testing against a range of drugs to support personalized clinical decision-making. The company's goal is to improve patient care by creating a healthier society through better, faster, and more affordable disease treatments. Invitrocue aims to achieve this by providing valuable knowledge to the industry regarding optimal drug development strategies. Invitrocue has operations in Australia, China, Hong Kong, and Germany. For more information, please visit www.invitrocue.com.